Download the Article
Understanding Regulation and Validation Processes for Biomarkers
Understanding Regulation and Validation Processes for Biomarkers
Successfully Executing Biomarker Strategies
The successful execution of a biomarker strategy requires a flexible approach. Medpace offers an extensive menu of biomarkers that use state of the art techniques and provide results that enable patient stratification and improve prediction of drug efficacy and safety. Our central laboratory biomarker team is led by PhD level scientists who oversee the robust pipeline of new biomarker validations.
Medpace central lab and bioanalytical lab expertise in biomarker development and validation are enhanced by the experience and capabilities of our network of reference and strategic laboratory partners as a seamless service to our clients. We validate new biomarkers quickly in an industry-leading 10-12 weeks.
Our lab services include:
- Anatomical Pathology
- Companion Diagnostics
- Cytogenetics
- DNA/RNA Services
- Genomics Analysis
- FISH
- Flow Cytometry
- Fluorescence Microscopy
- Functional and Receptor Assays
- IHC Testing
- Large and Small Molecule Expertise
- Ligand Binding Assays
- Mass Spectrometry: LC/MS/MS, GC/MS
- Microbiology
- Multiplex Platforms
- PK/PD Testing
- Proteomics
- Virology
Global Labs – Fully Integrated for Efficiency
Because almost every clinical trial requires laboratory support, having wholly-owned entities with a broad range of capabilities and comprehensive test menus provides built-in efficiencies and collaboration. In concert with the Medpace CRO or working on standalone projects, experts from our central laboratories and bioanalytical laboratory can help plan and execute your testing needs.
